SBC Medical Q1 2026: Revenue Drops 9% Amid Franchise Fee Restructuring

SBC Medical Group Holdings posted first quarter 2026 financial results showing a 9% year-over-year revenue decline to $43 million, though the company maintains strong cash reserves and expanding franchise footprints. The Irvine-based Medical Services Organization, which trades on Nasdaq under the ticker SBC, attributed the decrease primarily to a strategic structural reform involving franchise fee revisions that took effect in April 2025.

According to the official press release distributed via STT Info, net income attributable to the company fell 47% to $11 million, with earnings per share dropping 48% to $0.11 for the three months ended March 31, 2026. The net income margin sat at 26%, representing a 19 percentage point decline from the prior year period.

CEO Yoshiyuki Aikawa framed the results as a structural transition rather than operational weakness. Excluding the franchise fee restructuring, core business performance remained solid. EBITDA came in at $18 million, down 26% year-over-year, but the EBITDA margin held at 43%—still a healthy level for a franchise-based healthcare management company (though down 10 percentage points from last year).

The numbers tell a story of deliberate trade-offs. SBC Medical chose to revise its franchise fee structure, accepting short-term revenue compression in exchange for what management believes is a more sustainable long-term model. This is the kind of decision that looks ugly on a quarterly earnings slide but might make sense when you're building a platform meant to last decades, not quarters.

Operational metrics show continued expansion despite the revenue headwinds. Franchise locations grew to 284 as of March 31, 2026, an increase of 33 locations from the same period in 2025. Customer count for the trailing twelve months reached 6.76 million, up 10% year-over-year. The repeat rate—customers visiting franchisee clinics twice or more—stood at 72%, indicating sticky demand for the aesthetic dermatology and medical services the company manages.

Independent analysis from StockTitan notes that the prior year's results benefited from a sizable, non-recurring gain on life insurance policy redemptions. This one-time windfall amplifies the apparent decline when comparing year-over-year figures. Operating cash flow actually strengthened to $9.2 million from $1.9 million in the prior period, helped by working capital movements and lower income tax payments.

The balance sheet remains robust. Cash and cash equivalents rose to $167.3 million as of March 31, 2026, against bank and other borrowings of $40.4 million. Total assets reached $388.0 million with total liabilities of $117.6 million. Stockholders' equity increased to $270.4 million. This liquidity position gives management flexibility to service debt, invest in intangible assets, and fund expansion without immediate pressure to cut costs aggressively.

SBC Medical operates across multiple healthcare verticals including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment, and ophthalmology. The company manages a diverse portfolio of clinic brands including Rize Clinic, Gorilla Clinic, AHH Clinic, JUN CLINIC, and OrangeTwist. This multi-brand strategy in the aesthetic dermatology field is central to the company's growth thesis.

Looking ahead, management outlined plans to expand non-aesthetic medical business segments and strengthen operational foundations in overseas markets. The company is also pursuing opportunities in the longevity market and plans to enhance services through AI utilization. These initiatives aim to build what Aikawa described as a sustainable and continuously growing healthcare platform.

The company listed on Nasdaq in September 2024 and was selected for inclusion in the Russell 3000 Index in June 2025. This index inclusion matters for institutional investors who track broad U.S. equity benchmarks. Being in the Russell 3000 means more eyes on the stock, more analyst coverage, and potentially more stable institutional ownership.

Investors can access the full earnings release, accompanying slides, and archived webcast of the conference call at the company's Investor Relations website. The earnings call was scheduled for May 14, 2026, at 8:30 a.m. Eastern Time, with a question-and-answer session following prepared remarks. Registration was required through a dedicated Zoom webinar link.

What matters here isn't whether the revenue decline looks good on a spreadsheet—it doesn't. What matters is whether the franchise fee restructuring actually creates a more sustainable business model. The 72% repeat rate suggests customers keep coming back. The 33 new locations suggest franchisees are still willing to invest. The $167 million cash pile suggests the company can weather short-term volatility.

Whether the franchise fee changes actually improve long-term profitability without cannibalizing growth remains to be seen. Healthcare franchise models live or die by unit economics, and those don't always show up cleanly in quarterly reports. The real test will be whether SBC Medical can maintain its EBITDA margins while continuing to expand internationally.

For now, the company has the cash to keep experimenting. Whether users and franchisees actually pay for the new structure over the long term is the real question. Time will tell if this was a strategic pivot or just a way to smooth out the numbers before the next growth push.

Artūras Malašauskas is an AI Systems Integrator with 20+ years of production-grade web engineering experience. He has designed, shipped, and scaled enterprise Python/PHP systems for logistics, SaaS, and public-sector clients. For the past year, he has focused exclusively on AI integrations: deploying open-source LLMs, building generative media pipelines (image, audio, video), and engineering multi-agent workflows for real production environments. His standard: reproducibility, security, cost-efficient inference—no vaporware. He documents and evaluates emerging AI tooling, separating verified capabilities from marketing noise. Technical editor at: muza-ai.eu, ai-verslas.lt, ai-naujinos.lt Connect on LinkedIn